Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00487682
Status:
COMPLETED
Last Update Posted:
2018-11-23
First Post:
2007-06-15
Brief Title:
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
Dose-finding Study of ASP2151 in Subjects With Herpes Zoster- A Multicenter Randomized Double-blind Valacyclovir Hydrochloride-controlled Parallel-group Comparative Study
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the efficacy and safety of three different doses of ASP2151 as compared to valacyclovir hydrochloride in subjects with herpes zoster and to determine the recommended clinical dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None